These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18559644)

  • 1. Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
    Holodniy M; Penzak SR; Straight TM; Davey RT; Lee KK; Goetz MB; Raisch DW; Cunningham F; Lin ET; Olivo N; Deyton LR
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3013-21. PubMed ID: 18559644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature.
    Raisch DW; Straight TM; Holodniy M
    Pharmacotherapy; 2009 Aug; 29(8):988-92. PubMed ID: 19637952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of oseltamivir when coadministered with probenecid.
    Rayner CR; Chanu P; Gieschke R; Boak LM; Jonsson EN
    J Clin Pharmacol; 2008 Aug; 48(8):935-47. PubMed ID: 18524996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
    Maltezou HC; Drakoulis N; Siahanidou T; Karalis V; Zervaki E; Dotsikas Y; Loukas YL; Theodoridou M
    Pediatr Infect Dis J; 2012 May; 31(5):527-9. PubMed ID: 22209917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
    Pai MP; Lodise TP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5640-5. PubMed ID: 21930881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
    Reisinger K; Shu D; Cupelli L; Marcadis I; Dutkowski R
    Influenza Other Respir Viruses; 2013 Jan; 7(1):11-3. PubMed ID: 22520945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
    Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
    Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
    Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A part-randomized study of intravenous oseltamivir in adolescents and adults.
    Várkonyi I; Chappey C; Giraudon M; Burleigh L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
    Deleu S; Kakuda TN; Spittaels K; Vercauteren JJ; Hillewaert V; Lwin A; Leopold L; Hoetelmans RMW
    Br J Clin Pharmacol; 2018 Nov; 84(11):2663-2672. PubMed ID: 30098042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
    Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.